Market Access Views & Analysis

Views & Analysis

Market Access

Collaboration is key to tackling geographical boundaries in ...

Unlike most biopharmaceuticals, it is often a struggle to manufacture cell and gene therapies (CGTs) in disparate geographies.

Market Access

Which companies will last? Success begins with the basics

Founding a new company is a high stakes business. Many leaders begin with an exciting, well-funded solution and then struggle to build a sustainable business over time.

Market Access

NICE and the controversy over a ‘clinically distinct disease...

Payers worldwide are struggling with a new generation of precision medicines that come with a hefty price tag.

Market Access

Who delays NICE technology appraisals anyway?

Leela Barham looks at the speediness of NICE’s technology appraisals and ongoing efforts to hit the target of NICE publishing final guidance within 90 days of marketing authorisation.

Market Access

What are the key immigration changes facing the pharma indus...

It’s no secret that the UK life sciences sector is facing skills shortages – in a 2020 report, the Science Industry Partnership’s Life Sciences 2030 Skills Strategy predicted that 133,000 e

Market Access